Impact of Existing and Emerging Hypertrophic Cardiomyopathy Therapeutics Market

According to a recent market study published by Transparency Market Research (TMR), the global hypertrophic cardiomyopathy therapeutics market is anticipated to witness tepid growth over the next seven years, the global hypertrophic cardiomyopathy therapeutics market is forecast to rise from a value of US$1.2 bn in 2014 to US$1.4 bn in 2023, registering a 1.40% CAGR during that time.

The rising prevalence of chronic cardiovascular diseases, increased awareness about hypertrophic cardiomyopathy, and the growing demand for effective treatments options are the key factors fueling the hypertrophic cardiomyopathy therapeutics market. However, technological upgradation in devices such as pacemakers and defibrillators hampers the demand for hypertrophic cardiomyopathy drugs.
 
On the basis of drug class, the hypertrophic cardiomyopathy therapeutics market is categorized into calcium channel blockers, anticoagulants, beta adrenergic blocking agents, and antiarrhythmic agents. By revenue, calcium channel blockers held the largest share in 2014 and this trend is likely to continue through 2023 with the segment expanding at a 1.80% CAGR during that time. By demand, beta adrenergic blocking agents dominated the market given that they are the first choice for treatment of obstructive and non-obstructive hypertrophic cardiomyopathy.

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7553

The beta adrenergic blocking agent segment is projected to expand at the second highest CAGR during the forecast period from 2015 to 2023, as it is the first choice of treatment for obstructive and non-obstructive HCM. The antiarrhythmic and anticoagulants drug segments held the third and fourth largest shares of the global market in terms of revenue in 2014. However, rising technological upgrade of devices such as defibrillators and pacemakers could restraint market growth. The hypertrophic cardiomyopathy therapeutics market is likely to be driven by increase in sedentary lifestyle among the young population and rise in obese population.
 
Geographically, the hypertrophic cardiomyopathy therapeutics market has been segmented into four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). The market is primarily concentrated in the U.S., followed by Europe. The U.S. was the most attractive market for hypertrophic cardiomyopathy therapeutics in 2014, with more than 30% share of the global market. Europe accounted for the second-largest share of the global market in 2014. In 2014, the U.S. and Europe primarily dominated the hypertrophic cardiomyopathy therapeutics market due to modern healthcare infrastructure, increasing sedentary lifestyle among the youth, and rising obese population. Additionally, high awareness about HCM in developed countries boosts the market growth. North America is expected to continue its dominance during the forecast period. Asia Pacific was the fastest growing markets due to rising disease prevalence, developing healthcare infrastructure, and increasing awareness about cardiac complications in these regions. However, technological advancements in devices such as defibrillators and pacemakers are estimated to hamper market growth. This, in turn, would restrict the uptake of hypertrophic cardiomyopathy drugs. Thus, market leaders are recommended to focus on the development of new drugs or combination drugs that are specifically targeted toward hypertrophic cardiomyopathy in order to gain competitive advantage in the market.

AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG are some of the major companies operating in the global hypertrophic cardiomyopathy therapeutics market.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
 
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
 
Contact
Mr. Sudip Saha
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/